Dysregulation of sphingolipid metabolism in cancer
Dysregulation of sphingolipid metabolism in cancer
复制标题
DOI：
10.4161/cbt.11.2.14624
复制
发表时间：
2011-01-15
影响因子：
3.6
通讯作者：
Kester, Mark
中科院分区：
文献类型：
--
作者：
Ryland, Lindsay K.;Fox, Todd E.;Kester, Mark
鞘磷脂代谢的改变有助于癌症的进展，并为开发新的化疗药物提供了一个可开发的靶点。生物活性鞘脂代谢物也有可能作为癌症的重要生物标志物，并被用于确定疾病进展，以及指导治疗方案。此外，基于鞘脂组学的最新技术进步，这些鞘脂生物标志物的识别是可以实现的，这有助于通过质谱学等工具检测鞘脂代谢物。以往的优秀综述主要集中在鞘磷脂在癌症发病机制和治疗中的生化作用。本综述的目的是集中于导致鞘磷脂代谢失调的关键代谢物和酶，并重点介绍相关的翻译研究，以期找到新的治疗方法。
Altered sphingolipid metabolism contributes to cancer progression and presents an exploitable target for the development of novel chemotherapeutics. Bioactive sphingolipid metabolites also have the potential to serve as vital biomarkers for cancer and be utilized to determine disease progression, as well as guide therapeutic regimens. Moreover, identification of these sphingolipid biomarkers is achievable based on recent technological advances in sphingolipidomics, which have aided in detection of sphingolipid metabolites through tools like mass spectrometry. Excellent reviews have previously focused on the biochemical role that sphingolipids have in cancer pathogenesis and treatment. The aim of this review is to concentrate on the critical metabolites and enzymes that contribute to the dysregulation in sphingolipid metabolism, and highlight relevant translational research that is directed towards novel therapies.